OPM Publishes Its Annual Results for 2023 and Provides an Update on Its Clinical Developments

DIJON, France--(BUSINESS WIRE)--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancer, has published its financial results for 2023, as approved by the Board of Directors on 26 March 2024. Philippe Genne, Chairman and CEO of Oncodesign Precision Medicine, said: “One year after its launch, OPM and its teams have achieved a number of significant